UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.

Icosavax, a US-based vaccine developer spun out of University of Washington (UW), floated in a $182m initial public offering on Thursday on the Nasdaq Global Select Market.
The company issued some 12 million shares having priced them in the middle of the IPO’s $14 to $16 range. They opened at $29 each before closing at $35, representing a 133% increase.
Spun out of UW’s Institute for Protein Design, Icosavax is developing vaccines for respiratory illnesses using virus-like…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in